CORDIS
EU research results

CORDIS

English EN

Nanotherapeutics to Treat Antibiotic Resistant Gram-Negative Pneumonia Infections

Objective

The main objective of PneumoNP is the development of a theragnostic system for the treatment of lung Gram-negative bacterial infections. As a proof of concept PneumoNP will focus the attention on Klebsiella pneumoniae caused infections. A diagnostic kit will be developed to enable a rapid and precise identification of the bacteria strain causing the infection and avoid the use of wide spectrum antibiotics. For the treatment a nanotherapeutic based inhalable antibiotic will be developed. The therapeutic nanosystem will be based on a nanocarrier combined with an antimicrobial peptide. 3 different types of NCs will be tested with 2 AMPs to be able to obtain a novel effective inhalable antimicrobial NS. Nanotherapeutics offers many advantages in pulmonary drug-delivery, due to the huge surface area available in the lungs and their potential to achieve uniform distribution of drug dose among the alveoli. To improve this delivery to the lungs an aerosol system will also be developed. Due to the characteristics related to pulmonary delivery of NCs, topical and systemic bioavailabilities are envisaged. A diagnostic kit will be generated to monitor the efficacy and efficiency of the therapy. Once this treatment is proved to be effective, it could then be applied to any Gram-negative lung bacterial infection.
The number of antibiotic resistant bacteria strains is increasing rapidly, new types of therapy are urgently required to avoid the use of standard antibiotics. Gram-negative bacteria that cause pneumonia are one of the main sources of nosocomial infections, mainly in people with a weakened immune system. Apart from pneumonia they can cause bacteremia and other infections. Early detection of the infection source combined with the development of appropriate and effective NSs to treat multi-drug resistant (MDR) bacteria caused infections will definitely radically improve the healing process of patients and avoid complications for people in hospital.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FUNDACION CIDETEC

Address

Paseo Miramon 196 Parque Tecnologico De Miramon
20014 San Sebastian

Spain

Activity type

Research Organisations

EU Contribution

€ 896 660

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

ADENIUM BIOTECH APS

Denmark

EU Contribution

€ 416 300

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE

Spain

EU Contribution

€ 555 990,80

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 975 861,20

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 332 340

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 511 251,25

INGENIATRICS TECNOLOGIAS SL

Spain

EU Contribution

€ 454 658

PATHOFINDER BV

Netherlands

EU Contribution

€ 497 681,60

SETLANCE SRL

Italy

EU Contribution

€ 341 902,40

UMAPS COMMUNICATION SARL

France

EU Contribution

€ 183 520

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 516 185,75

Project information

Grant agreement ID: 604434

Status

Closed project

  • Start date

    1 January 2014

  • End date

    31 December 2017

Funded under:

FP7-NMP

  • Overall budget:

    € 7 510 269,74

  • EU contribution

    € 5 682 351

Coordinated by:

FUNDACION CIDETEC

Spain

This project is featured in...